
Armata Pharmaceuticals Secures $2.5M DoD Boost for Phage Therapy
The U.S. Department of Defense has granted Armata Pharmaceuticals an additional $2.5 million to accelerate the development of its lead candidate, AP-SA02. This non-dilutive funding, processed through the Medical Technology Enterprise Consortium, brings the total federal investment in the program to $28.7 million as the company prepares for Phase 3 trials.

























